Opendata, web and dolomites

DRIVE SIGNED

Diabetes Reversing Implants with enhanced Viability and long-term Efficacy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DRIVE project word cloud

Explore the words cloud of the DRIVE project. It provides you a very rough idea of what is the project "DRIVE" about.

demand    mellitus    worldwide    gels    islet    t1d    hydrogels    invasive    glycemic    limit    macrocapsule    tuneable    people    time    residence    vein    disease    characterised    porous    islets    sensitive    sufferers    diabetes    omental    poor    lifelong    therapy    t2    portal    bio    retrievable    models    compatibility    degradation    shell    specialised    human    beta    pancreatic    extended    sources    vivo    biofunctionalised    cell    injection    extremely    drug    engraftment    localised    supply    safe    containing    isdm    procedure    technologies    efficacy    cath    pluripotent    transplantation    cues    glucose    million    retention    suite    blood    housed    survival    fold    dimensional    insulin    profiles    storage    protective    inadequate    interactive    laparoscopic    donor    release    t1    cells    microencapsulated    stem    chronic    immunoprotection    yield    microparticles    handling    polymeric    diabetics    cure    preservation    resistance    added    experts    peritoneum    immunosuppressive    minimally    brittle    catheter    oxygenation    injectable    create    382    deposition    transport    clinical    vitro    ease    systemic    risk    treatment    vascularisation    drive    gel    agents    harvesting   

Project "DRIVE" data sheet

The following table provides information about the project.

Coordinator
NATIONAL UNIVERSITY OF IRELAND GALWAY 

Organization address
address: UNIVERSITY ROAD
city: Galway
postcode: H91
website: www.nuigalway.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.drive-project.eu
 Total cost 8˙832˙062 €
 EC max contribution 8˙832˙061 € (100%)
 Programme 1. H2020-EU.2.1.3.1. (Cross-cutting and enabling materials technologies)
 Code Call H2020-NMP-2014-two-stage
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NATIONAL UNIVERSITY OF IRELAND GALWAY IE (Galway) coordinator 435˙576.00
2    ABIEL SOCIETA A RESPONSABILITA LIMITATA IT (PALERMO) participant 887˙366.00
3    EXPLORA SRL IT (ROMA) participant 820˙000.00
4    ROYAL COLLEGE OF SURGEONS IN IRELAND IE (DUBLIN) participant 812˙141.00
5    BOSTON SCIENTIFIC LIMITED IE (GALWAY) participant 715˙020.00
6    UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN IE (DUBLIN) participant 700˙496.00
7    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 679˙153.00
8    INNOCORE TECHNOLOGIES BV NL (Groningen) participant 600˙812.00
9    CONTIPRO AS CZ (DOLNI DOBROUC) participant 600˙625.00
10    DUBLIN CITY UNIVERSITY IE (DUBLIN) participant 600˙000.00
11    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 579˙113.00
12    CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. ES (MADRID) participant 550˙452.00
13    UNIVERSITEIT UTRECHT NL (UTRECHT) participant 498˙555.00
14    INNOVA SRL IT (ROMA) participant 273˙000.00
15    L'AZIENDA SOCIO SANITARIA TERRITORIALE (ASST) GRANDE OSPEDALE METROPOLITANO NIGUARDA IT (MILANO) participant 79˙750.00
16    AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA IT (MILANO) participant 0.00

Map

 Project objective

Diabetes mellitus is a chronic disease characterised by high blood glucose due to inadequate insulin production and/or insulin resistance which affects 382 million people worldwide. Pancreatic islet transplantation is an extremely promising cure for insulin-sensitive diabetes mellitus (ISDM), but side effects of lifelong systemic immunosuppressive therapy, short supply of donor islets and their poor survival and efficacy in the portal vein limit the application of the current clinical procedure to the most at-risk brittle Type I diabetes (T1D) sufferers. The DRIVE consortium will develop a novel suite of bio-interactive hydrogels (β-Gel) and on-demand drug release systems to deliver islets in a protective macrocapsule (β-Shell) to the peritoneum with targeted deposition using a specialised injection catheter (β-Cath). Pancreatic islets will be microencapsulated in β-Gels; biofunctionalised injectable hydrogels containing immunosuppressive agents and polymeric microparticles with tuneable degradation profiles for localised delivery of efficacy cues. These β-Gels will be housed in a porous retrievable macrocapsule, β-Shell, for added retention, engraftment, oxygenation, vascularisation and immunoprotection of the islets. A minimally invasive laparoscopic procedure (O-Fold) will be used to create an omental fold and at the same time deliver β-Shell. An extended residence time in β-Gel will enhance long-term clinical efficacy of the islets and result in improved glycemic control. The novel β-Gels will also be developed as human three-dimensional in-vitro models of in-vivo behaviour. Islet harvesting and preservation technologies will be developed to facilitate their optimised yield, safe handling and transport, and ease of storage. DRIVE will also enable the future treatment of a broader range of T1 and insulin-sensitive T2 diabetics by working with induced pluripotent stem cell experts to ensure the compatibility of our system with future stem cell sources of β-cells.

 Deliverables

List of deliverables.
Dissemination and Data Management Plan (DMP) and introductory project dissemination material Documents, reports 2019-10-08 17:13:00
Outcomes of patients and citizens panel’s report Documents, reports 2019-10-08 17:12:44
Project website Websites, patent fillings, videos etc. 2019-10-08 17:12:40
Report on patient advocacy activities Documents, reports 2019-10-08 17:13:00

Take a look to the deliverables list in detail:  detailed list of DRIVE deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Aline Zbinden, Julia Marzi, Katharina Schlünder, Christopher Probst, Max Urbanczyk, Scott Black, Eva M. Brauchle, Shannon L. Layland, Udo Kraushaar, Garry Duffy, Katja Schenke-Layland, Peter Loskill
Non-invasive marker-independent high content analysis of a microphysiological human pancreas-on-a-chip model
published pages: , ISSN: 0945-053X, DOI: 10.1016/j.matbio.2019.06.008
Matrix Biology 2019-08-30
2018 Federico Bertuzzi, Luciano De Carlis, Mario Marazzi, Antonio Gaetano Rampoldi, Matteo Bonomo, Barbara Antonioli, Marta Cecilia Tosca, Marta Galuzzi, Andrea Lauterio, Danila Fava, Patrizia Dorighet, Andrea De Gasperi, Giacomo Colussi
Long-term Effect of Islet Transplantation on Glycemic Variability
published pages: 840-846, ISSN: 0963-6897, DOI: 10.1177/0963689718763751
Cell Transplantation 27/5 2019-08-30
2017 Alan J .Ryan, Hugh S O’Neill, Garry P Duffy, Fergal J O’Brien
Advances in polymeric islet cell encapsulation technologies to limit the foreign body response and provide immunoisolation
published pages: 66-71, ISSN: 1471-4892, DOI: 10.1016/j.coph.2017.07.013
Current Opinion in Pharmacology 36 2019-08-30
2018 Albert Espona-Noguera, Jesús Ciriza, Alberto Cañibano-Hernández, Luis Fernandez, Ignacio Ochoa, Laura Saenz del Burgo, Jose Luis Pedraz
Tunable injectable alginate-based hydrogel for cell therapy in Type 1 Diabetes Mellitus
published pages: 1261-1269, ISSN: 0141-8130, DOI: 10.1016/j.ijbiomac.2017.09.103
International Journal of Biological Macromolecules 107 2019-08-30
2017 S. Acreman, H. Brandhorst, A. Abraham, P.R.V. Johnson, D. Brandhorst
Effect of Etanercept Concentration on Human Islet Integrity
published pages: 2327-2329, ISSN: 0041-1345, DOI: 10.1016/j.transproceed.2017.11.002
Transplantation Proceedings 49/10 2019-08-30
2018 Bertuzzi F, Colussi G, Lauterio A, De Carlis L.
Intramuscular islet allotransplantation in type 1 diabetes mellitus.
published pages: , ISSN: 1128-3602, DOI: 10.26355/eurrev_201803_14588
Eur Rev Med Pharmacol Sci 2019-08-30
2019 Karina C. Scheiner, Roel F. Maas-Bakker, Thanh T. Nguyen, Ana M. Duarte, Gert Hendriks, Lídia Sequeira, Garry P. Duffy, Rob Steendam, Wim E. Hennink, Robbert J. Kok
Sustained Release of Vascular Endothelial Growth Factor from Poly(ε-caprolactone-PEG-ε-caprolactone)- b -Poly( l -lactide) Multiblock Copolymer Microspheres
published pages: 11481-11492, ISSN: 2470-1343, DOI: 10.1021/acsomega.9b01272
ACS Omega 4/7 2019-08-30

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DRIVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DRIVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.3.1.)

BIOCAPAN (2015)

BIOactive implantable CApsule for PANcreatic islets immunosuppression free therapy

Read More  

ELASTISLET (2015)

Tailored Elastin-like Recombinamers as Advanced Systems for Cell Therapies in Diabetes Mellitus: a Synthetic Biology Approach towards a Bioeffective and Immunoisolated Biosimilar Islet/Cell Niche

Read More  

MOSTOPHOS (2015)

Modelling stability of organic phosphorescent light-emitting diodes

Read More